Onderzoeker
Armand Van Deun
- Trefwoorden:B230-bacteriologie, B680-volksgezondheid, B725-diagnostiek, B726-klinische-biologie
Affiliaties
- Mycobacteriologie (Onderzoekseenheid)
Lid
Vanaf31 dec 1998 → 29 nov 2018 - Mycobacteriologie (Onderzoekseenheid)
Lid
Vanaf31 dec 1998 → 16 apr 2015
Projecten
1 - 4 of 4
- Novel High-Dose Tuberculosis Retreatment Regimens: How to overcome resistance without Creating MoreVanaf1 okt 2018 → Heden
- Trend and significance of INH resistance in DF BdeshVanaf1 jan 2018 → 31 dec 2018
- Trend of fluoroquinolone resistance among the MDR in DF BangladeshVanaf1 jan 2017 → 31 dec 2018
- Validity and feasability of use of a rapid and innovative test for detection of Multi Drug Resistant (MDR) TB cases in Kinshasa, DRCVanaf1 mrt 2009 → 6 jul 2018
Publicaties
11 - 20 van 142
- Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment(2022)
Auteurs: Sophia B. Georghiou, Timothy C. Rodwell, Alexei Korobitsyn, Said H. Abbadi, Kanchan Ajbani, Jan-Willem Alffenaar, David Alland, Nataly Alvarez, Sonke Andres, Elisa Ardizzoni, et al.
- How second-line injectable drugs work(2021)
Auteurs: Armand Van Deun, Tom Decroo
Pagina's: e1167-e1168 - Finding the right balance between efficacy and tolerability for TB treatment: the search continues(2021)
Auteurs: A.K.J. Maug, M.A. Hossain, M Gumusboga, Tom Decroo, W Mulders, Sofie Braet, Jozefien Buyze, D A Jiménez, Céline Schurmans, Natacha Herssens, et al.
Pagina's: 84-86 - Thin-layer-agar-based direct phenotypic drug susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance otherwise missed by WHO-endorsed diagnostic tests(2021)
Auteurs: Elisa Ardizzoni, E. Ariza, D. Mulengwa, Q. Mpala, R de la Tour, Gugu Maphalala, F. Varaine, Bernhard Kerschberger, Pieter Graulus, A-L Page, et al.
- Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?(2021)
Auteurs: Sabira Tahseen, A Van Deun, Bouke de Jong, Tom Decroo
Pagina's: 831-835 - Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial(2021)
Auteurs: Mebrat Ejo Kitata, A Van Deun, A Nunn, SEO Meredith, S. Ahmed, D. Dalai, O. Tumenbayar, B. Tsogt, P. T. Dat, D. T. M. Ha, et al.
Pagina's: 839-845 - Should treatment of low-level rifampicin mono-resistant tuberculosis be different?(2021)
Auteurs: Armand Van Deun, Tom Decroo
- Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown(2021)
Auteurs: Armand Van Deun, Tom Decroo, Kya Jai Maug Aung, Mohamed Anwar Hossain, M Gumusboga, P De Rijk, Sabira Tahseen, Bouke de Jong, L Rigouts
- Low cycle threshold value in Xpert MTB/RIF assay may herald false detection of tuberculosis and rifampicin resistance: a study of two cases(2021)
Auteurs: Jean Claude Semuto Ngabonziza, Tom Decroo, Rodrigue Maniliho, Yves Mucyo Habimana, Armand Van Deun, Bouke de Jong
- Human rights: finding the right balance for rifampicin-resistant TB treatment(2021)
Auteurs: Armand Van Deun, A Piubello, Lutgarde Lynen, Bouke de Jong, Tom Decroo
Pagina's: 327-328